From Oncology Nurse Advisor:
MicroRNAs (miRNAs) predict response to treatment with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC). The miRNAs define patients refractory to TKI therapy who have a poor prognosis. TKIs are antiangiogenic drugs used frequently to treat renal cell carcinoma.
Read the full article.
